Oral HDAC inhibitor tucidinostat in people with relapsed or refractory peripheral T-cell lymphoma: period IIb resultsQuite a few ongoing scientific investigations examine tucidinostat use in various combos for relapsed along with newly diagnosed PTCL (Tables three–five), demonstrating that tucidinostat can produce synergistic consequences with ot